Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of SAR442168 in relapsing multiple sclerosis
NL-OMON54729Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tolebrutinib in multiple sclerosis (MS), sponsored by Sanofi. Primary endpoints: Adverse events and serious adverse events and MRI safety findings. Started Dec 2019; status: completed.
02
Drugs
tolebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON54729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54729.